@article{01GSA3P9HKKJ256W571XZWMP12,
  abstract     = {{Background and purpose: To investigate the association between clinician-scored toxicities and patient -reported health-related quality of life (HRQoL), in early-stage (ES-) and locally-advanced (LA-) non -small cell lung cancer (NSCLC) patients receiving loco-regional radiotherapy, included in the international real-world REQUITE study.Materials and methods: Clinicians scored eleven radiotherapy-related toxicities (and baseline symptoms) with the Common Terminology Criteria for Adverse Events version 4. HRQoL was assessed with the European Organization for Research and Treatment of Cancer core HRQoL questionnaire (EORTC-QLQ-C30). Statistical analyses used the mixed-model method; statistical significance was set at p = 0.01. Analyses were performed for baseline and subsequent time points up to 2 years after radiotherapy and per treatment modality, radiotherapy technique and disease stage. Results: Data of 435 patients were analysed. Pre-treatment, overall symptoms, dyspnea, chest wall pain, dysphagia and cough impacted overall HRQoL and specific domains. At subsequent time points, cough and dysphagia were overtaken by pericarditis in affecting HRQoL. Toxicities during concurrent chemo-radiotherapy and 3-dimensional radiotherapy had the most impact on HRQoL. Conversely, toxicities in sequential chemo-radiotherapy and SBRT had limited impact on patients' HRQoL. Stage impacts the cor-relations: LA-NSCLC patients are more adversely affected by toxicity than ES-NSCLC patients, mimicking the results of radiotherapy technique and treatment modality.Conclusion: Pre-treatment symptoms and acute/late toxicities variously impact HRQoL of ES-and LA-NSCLC patients undergoing different treatment approaches and radiotherapy techniques. Throughout the disease, dyspnea seems crucial in this association, highlighting the additional effect of co-existing comorbidities. Our data call for optimized radiotherapy limiting toxicities that may affect patients' HRQoL.Crown Copyright (c) 2022 Published by Elsevier B.V. All rights reserved. Radiotherapy and Oncology 176 (2022) 127-137}},
  author       = {{van der Weijst, Lotte and Azria, David and Berkovic, Patrick and Boisselier, Pierre and Briers, Erik and Bultijnck, Renée and Chang-Claude, Jenny and Choudhury, Ananya and Defraene, Gilles and Demontois, Sylvian and Elliott, Rebecca M. and Ennis, Dawn and Faivre-Finn, Corinne and Franceschini, Marzia and Giandini, Tommaso and Giraldo, Alexandra and Gutiérrez-Enríquez, Sara and Herskind, Carsten and Higginson, Daniel S. and Kerns, Sarah L. and Johnson, Kerstie and Lambrecht, Maarten and Lang, Philippe and Ramos, Mónica and Rancati, Tiziana and Rimner, Andreas and Rosenstein, Barry S. and De Ruysscher, Dirk and Salem, Ahmed and Sangalli, Claudia and Seibold, Petra and Sosa Fajardo, Paloma and Sperk, Elena and Stobart, Hilary and Summersgill, Holly and Surmont, Veerle and Symonds, Paul and Taboada-Valladares, Begoña and Talbot, Christopher J. and Vega, Ana and Veldeman, Liv and Veldwijk, Marlon R. and Ward, Tim and Webb, Adam and West, Catharine M.L. and Lievens, Yolande and Consortium, REQUITE}},
  issn         = {{0167-8140}},
  journal      = {{RADIOTHERAPY AND ONCOLOGY}},
  keywords     = {{Radiology, Nuclear Medicine and imaging,Oncology,Hematology,Association,Non-small cell lung cancer,Radiotherapy,Patient-reported outcomes,Toxicity,Health-related quality of life}},
  language     = {{eng}},
  pages        = {{127--137}},
  publisher    = {{Elsevier BV}},
  title        = {{The correlation between pre-treatment symptoms, acute and late toxicity and patient-reported health-related quality of life in non-small cell lung cancer patients : results of the REQUITE study}},
  url          = {{http://doi.org/10.1016/j.radonc.2022.09.020}},
  volume       = {{176}},
  year         = {{2022}},
}

Altmetric

View in Altmetric

Web of Science

Times cited: